Larvol Delta - Aspen-Neuroscienceannounced-completion-of-dosing-in-Cohort-3-and-Cohort-4-of-its-ongoing-Phase-12a-ASPIRO-clinical-trial-evaluating-sasineprocel-ANPD001-for-the-treatment-of-Parkinson39s-disease-PD

sasineprocel (ANPD001) - Aspen Neurosci

https://www.prnewswire.com/news-releases/aspen-neuroscience-announces-completion-of-cohort-3-and-4-dosing-in-aspiro-phase-12a-trial-of-sasineprocel-for-parkinsons-disease-302813731.html

Jun 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next